Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
Date:4/16/2008

INS-19 Receives Regulatory Clearance

RICHMOND, Va., April 16 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate the Company's first clinical study for a follow-on biologic (FOB) product candidate. Insmed's INS-19, which is a recombinant form of human G-CSF, is a follow-on biologic of the FDA-approved product Neupogen(R), which had U.S. sales of approximately $0.9 billion in 2007.

Pre-clinical studies demonstrate that INS-19 and FDA-approved Neupogen(R) are comparable in both their pharmacological and toxicological profile. Detailed analytical characterisation also demonstrates that the products have a high degree of similarity. Data from these initial evaluations have been used, in part, to support the Phase I study, which will be initiated immediately. The Phase I study will be conducted in the UK and will compare the safety and establish the bioequivalence of INS-19 to Neupogen(R). Results from the trial are expected in the second half of 2008, and are planned to be used as part of a submission to the FDA to establish a protocol with the agency for a Phase III trial in the U.S.

"By utilizing Insmed's unique protein drug development capabilities and technical expertise, the Company has been able to advance a follow-on biologic product candidate from project initiation to human testing in less than one year, a significant achievement," said Geoffrey Allan, CEO of Insmed. "We intend to utilize the data generated from the Phase I trial, in combination with the positive preclinical results previously garnered, as the basis for discussions with the FDA in an effort to establish a Phase III development path for INS-19."

The initiation of this follow-on biologic trial is the first of two planned for 2008 as part of Insme
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
6. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Metabolex Initiates Phase 1 Trial of MBX-2982
11. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... ROCHESTER, N.Y. and LONDON ... VSCP ) and IXICO plc (AIM: IXI) jointly ... that will benefit both companies. Dr. Edward Ashton ... Board which initially will have seven members. ... an important initiative of the international commercial and operational ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... 2014 According to a ... of Material, Application (Healthcare, Homeland security, Industrial application, ... Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) & ... published by MarketsandMarkets, the Scintillator Market is expected ... 2014 to 2020, and reach $479.16 Million in ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... Leading health sciences publisher makes key ... UN developing world research access program ... information products and services, today announced that it is ... , a public-private partnership working to achieve the UN,s ...
... (NASDAQ: LMNX ) today announced that it expects ... on Tuesday, November 1, 2011.  A press release announcing ... of trading. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the third quarter ...
Cached Medicine Technology:Elsevier Offers 950 New Health Titles to Research4Life 2Elsevier Offers 950 New Health Titles to Research4Life 3Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011 2Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011 3
(Date:7/14/2014)... Francisco, California (PRWEB) July 14, 2014 ... expected to reach USD 4,285.1 million by 2020 ... a new study by Grand View Research, Inc. ... computational biology for bioinformatics R&D programs designed for ... increasing number of clinical studies in pharmacogenomics and ...
(Date:7/14/2014)... July 14, 2014 July 14, ... leader in enterprise-class cloud management, governance, and compliance ... announced AvePoint software will be available to customers ... specialist. , The hosting and value-added ... the following AvePoint solutions to new or existing ...
(Date:7/14/2014)... 14, 2014 “You've probably heard the ... does that mean?” This question was posed in an ... Western Washington Medical Group’s blog regarding how people should ... in mind . , According to the article, individuals ... themselves at a high risk of dehydration and consequent ...
(Date:7/14/2014)... WA (PRWEB) July 14, 2014 Sometimes, ... up company Passionate Playground announces its first product release, ... pleasure product storage system. , Inventor and ... passionate consumers to have a storage solution for their ... the multibillion dollar adult retail industry. , Semer met ...
(Date:7/14/2014)... A new analysis has found that rates of testicular ... young Hispanic American men, but not among their non-Hispanic ... peer-reviewed journal of the American Cancer Society, the findings ... risk of testicular cancer in Hispanic adolescents and young ... the cause of this trend. , Testicular cancer is ...
Breaking Medicine News(10 mins):Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:Testicular cancer rates are on the rise in young Hispanic Americans 2
... GBM, is a brain cancer death sentence. It is the ... people who are diagnosed with GBM annually in the U.S., ... the rest within 3 years. The treatments include highly invasive ... maximum tolerated dose, both leading to a very low quality ...
... conducted by the University of Michigan’s researchers has revealed that those ... unsafe are likely to put on weight. As many as 16% ... in the US are reported to be overweight, while in the ... tripled since the early 1990s. ,The researchers, led ...
... drinkers world over have one more reason to raise a ... news on how you // can pep-up your ... Wine Studies at Coventry University, and author of the formula ... the laws while popping open a champagne bottle. According to ...
... Cheerleaders tackle increasingly difficult acrobatic stunts and are paying the ... a study says. ,Cheerleaders catapult in the ... they fall to the ground. They also make it to ... in the journal Pediatrics estimates that 208,800 young people aged ...
... is mainly present in pain relievers. Recently there is an ... clinicians complaining about over dosage of Acetaminophen. ,Over ... of these cases are unintentional. Drugs like Tylenol, Benadryl, Contac, ... one of the main composition in them. ,Americans ...
... who have been smoking in the past have been recommended to ... to detect // lung cancer if any, at an early ... thereby improve the prognosis. ,The need for the ... the dreadful disease. For those of you who have still ...
Cached Medicine News:Health News:Radiology advance points way to non-invasive brain cancer treatment 2Health News:Surroundings Have An Effect On Weight 2Health News:Cheerleaders run high risk of injury-US study 2Health News:Painkillers Lead To Liver Failure 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... The Blue Line Wrist Control offers a ... wrist support for Carpal Tunnel Syndrome, tendinitis, ... the wrist. Careful design leaves fingers free ... wrist. Lightweight metal stay can be contoured ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Medicine Products: